Recruiting Clinical Trials

Nintedanib (BIBF 1120) in Mesothelioma

By April 24, 2017 No Comments

Condition

Mesothelioma

Estimated Enrollment: 537

Age Group: 18 Years and older   (Adult, Senior)

Gender: All

Study Type: Interventional

Study Design Allocation: Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (masked roles unspecified)|Primary Purpose: Treatment

Study ID Numbers: 1199.93|2012-005201-48

Study First Received: July 22, 2013

Last Updated: April 18, 2017

Estimated Primary Completion Date: October 30, 2019

 

Primary Outcome Measures:

Progression free survival measured from the time of randomisation to the time of disease progression or death of any cause, whichever occurs earlier|Overall survival measured from the time of randomisation to the time of death of any cause|Objective response according to modified RECIST analysed by objective response rate|Disease control according to modified RECIST analysed by disease control rate

Sponsors and Collaborators:

Boehringer Ingelheim

Website Link: https://ClinicalTrials.gov/show/NCT01907100

Leave a Reply

Call Now ButtonCall Now